Search Results

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the first quarter ending March 31, 2024.

Akoya Biosciences, Inc., The Spatial Biology Company®, and Shanghai KR Pharmtech have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China’s National Medical Products Administration to support next generation pathology clinical workflows.

Akoya Biosciences, Inc., The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients.

Akoya Biosciences, Inc., The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced that it has been named as a qualified contract research organization of Akoya Biosciences.